Bedirhan Boztepe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bedirhan Boztepe has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Douglas E. Vaughan
Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
2 shared publications - Alireza Khoddam
Feinberg Cardiovascular and Renal Research Institute
1 shared publication - Andrew Decker
Feinberg Cardiovascular and Renal Research Institute
1 shared publication - Anthony Kalousdian
Feinberg Cardiovascular and Renal Research Institute
1 shared publication - Arun Sivakumar
Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
1 shared publication - Baljash S. Cheema
Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
1 shared publication
Latest Publications
- Open Access
- 15 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (12)
Functional, molecular, and digital measurements of biological age
The reality of an aging population demands a deeper understanding of aging as a biological process, rather than as a chronological descriptor. Chronological age poorly captures interindividual heterogeneity in physiological and functional decline, disease susceptibility, and mortality risk. In contrast, biological age encompasses deterioration at the molecular, cellular, tissue, organ, functional, and organismal levels and provides insight into why two individuals with the same chronological age exhibit differences in physiological function, disease susceptibility, and mortality risk. While early models of biological age relied on functional markers or composite scores derived largely from longitudinal cohort studies, more recent models integrate molecular profiling with machine learning to ascertain biological aging trajectories. In parallel, new artificial intelligence tools have been applied to various imaging modalities and other forms of complex data to elucidate latent patterns and estimate biological age. In this state-of-the-art Review, we explore historical and modern approaches to estimating biological age and highlight key conceptual, technical, and translational challenges that remain unresolved. As geroscience-guided interventions are incorporated into clinical evaluations, robust and accurate interpretable measures of biological aging are crucial to ascertain treatment effects in clinical trials.
- 15 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (12)
Open AccessFunctional, molecular, and digital measurements of biological age
The reality of an aging population demands a deeper understanding of aging as a biological process, rather than as a chronological descriptor. Chronological age poorly captures interindividual heterogeneity in physiological and functional decline, disease susceptibility, and mortality risk. In contrast, biological age encompasses deterioration at the molecular, cellular, tissue, organ, functional, and organismal levels and provides insight into why two individuals with the same chronological age exhibit differences in physiological function, disease susceptibility, and mortality risk. While early models of biological age relied on functional markers or composite scores derived largely from longitudinal cohort studies, more recent models integrate molecular profiling with machine learning to ascertain biological aging trajectories. In parallel, new artificial intelligence tools have been applied to various imaging modalities and other forms of complex data to elucidate latent patterns and estimate biological age. In this state-of-the-art Review, we explore historical and modern approaches to estimating biological age and highlight key conceptual, technical, and translational challenges that remain unresolved. As geroscience-guided interventions are incorporated into clinical evaluations, robust and accurate interpretable measures of biological aging are crucial to ascertain treatment effects in clinical trials.
- Open Access
- 30 September 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (23)
Plasminogen activator inhibitor 1 promotes aortic aging–like pathophysiology in humans and mice
Plasminogen activator inhibitor 1 (PAI-1), encoded by SERPINE1 , contributes to age-related cardiovascular disease (CVD) and other aging-related pathologies. Humans with a heterozygous loss-of-function SERPINE1 variant exhibit protection against aging and cardiometabolic dysfunction. We engineered a mouse model mimicking the human mutation ( Serpine1 TA700/+ ) and compared cardiovascular responses with WT littermates. Serpine1 TA700/+ mice lived 17% longer than did littermate control mice. Under l-N G -nitro-arginine methyl ester–induced (l-NAME–induced) vascular stress, Serpine1 TA700/+ mice exhibited diminished pulse wave velocity (PWV), lower systolic blood pressure (SBP), and preserved left ventricular diastolic function compared with controls. Conversely, PAI-1–overexpressing mice had measurements indicating accelerated cardiovascular aging. Single-cell transcriptomics of Serpine1 TA700/+ aortas revealed a vascular-protective mechanism with downregulation of the extracellular matrix regulators Ccn1 and Itgb1 . Serpine1 TA700/+ aortas were also enriched in a cluster of smooth muscle cells that exhibited plasticity. Finally, PAI-1 pharmacological inhibition normalized SBP and reversed l-NAME–induced PWV elevation. These findings demonstrate that PAI-1 reduction protects against cardiovascular aging-related phenotypes, while PAI-1 excess promotes vascular pathological changes. Taken together, PAI-1 inhibition represents a promising strategy to mitigate age-related CVD.
- 30 September 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (23)
Open AccessPlasminogen activator inhibitor 1 promotes aortic aging–like pathophysiology in humans and mice
Plasminogen activator inhibitor 1 (PAI-1), encoded by SERPINE1 , contributes to age-related cardiovascular disease (CVD) and other aging-related pathologies. Humans with a heterozygous loss-of-function SERPINE1 variant exhibit protection against aging and cardiometabolic dysfunction. We engineered a mouse model mimicking the human mutation ( Serpine1 TA700/+ ) and compared cardiovascular responses with WT littermates. Serpine1 TA700/+ mice lived 17% longer than did littermate control mice. Under l-N G -nitro-arginine methyl ester–induced (l-NAME–induced) vascular stress, Serpine1 TA700/+ mice exhibited diminished pulse wave velocity (PWV), lower systolic blood pressure (SBP), and preserved left ventricular diastolic function compared with controls. Conversely, PAI-1–overexpressing mice had measurements indicating accelerated cardiovascular aging. Single-cell transcriptomics of Serpine1 TA700/+ aortas revealed a vascular-protective mechanism with downregulation of the extracellular matrix regulators Ccn1 and Itgb1 . Serpine1 TA700/+ aortas were also enriched in a cluster of smooth muscle cells that exhibited plasticity. Finally, PAI-1 pharmacological inhibition normalized SBP and reversed l-NAME–induced PWV elevation. These findings demonstrate that PAI-1 reduction protects against cardiovascular aging-related phenotypes, while PAI-1 excess promotes vascular pathological changes. Taken together, PAI-1 inhibition represents a promising strategy to mitigate age-related CVD.